Denali Therapeutics Inc. insider trading

Bought

—

Sold

$435.3K

3 of 5 on a 10b5-1 plan

Net

−$435.3K

Insiders

3

• Chin Peter Scott

  Chief Medical Officer

  −$36.9K

  Sep 04, 2026

  1,654 sh · $22.29

• Thornberry Nancy10b5-1

  Director

  −$247.3K

  Sep 02, 2026

  10,824 sh · $22.85

• Thornberry Nancy10b5-1

  Director

  −$14.6K

  Sep 02, 2026

  615 sh · $23.74

• Schuth Alexander O.10b5-1

  COFO and Secretary

  −$64.9K

  Sep 01, 2026

  2,768 sh · $23.44

• Schuth Alexander O.

  COFO and Secretary

  −$71.6K

  Aug 11, 2026

  2,857 sh · $25.07

Largest sale

−$7.4M of DNLI by Watts Ryan J. (President and CEO · Director) on Jul 09, 2025, under a 10b5-1 plan.

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

SEC industry classification

Biological Products, (No Diagnostic Substances)

Headquarters

South San Francisco, CA

Incorporated in

DE

Listed on

Nasdaq

SEC Central Index Key

0001714899

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

Open-market purchase (code P)

An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.

Grants and option exercises (codes A, M)

Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.

Cluster buy

Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Are DNLI insiders buying or selling?

Between Aug 11, 2026 and Sep 04, 2026, 3 Denali Therapeutics Inc. insiders made no open-market purchases and 5 sales worth $435.3K, a net sale of $435.3K. 3 of the sales were pre-scheduled under a Rule 10b5-1 plan.

How much DNLI stock have insiders bought and sold in the last two years?

Between Jul 01, 2024 and Jun 30, 2026, 6 Denali Therapeutics Inc. insiders made no open-market purchases and 41 sales worth $16.8M. 27 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 6 sales ($8.4M). The largest sale was Watts Ryan J. selling $7.4M on Jul 09, 2025.

What was the largest recent DNLI insider trade?

Thornberry Nancy (Director) sold $247.3K of DNLI stock on Sep 02, 2026 at about $22.85 a share, under a pre-scheduled 10b5-1 plan.

When did an insider last buy DNLI shares?

No open-market purchase by a Denali Therapeutics Inc. insider appears in the filings from Aug 11, 2026 to Sep 04, 2026 — every recorded open-market transaction in that period was a sale.

Where does DNLI insider trading data come from?

From the Form 4 filings Denali Therapeutics Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.